دورية أكاديمية
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.
| العنوان: | Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. |
|---|---|
| المؤلفون: | Araujo-Castro, Marta, Biagetti, Betina, Menéndez Torre, Edelmiro, Novoa-Testa, Iría, Cordido, Fernando, Pascual-Corrales, Eider, Rodríguez Berrocal, Víctor, Guerrero-Pérez, Fernando, Vicente, Almudena, Percovich Hualpa, Juan Carlos, García-Centeno, Rogelio, González-Fernández, Laura, Ollero García, María Dolores, Irigaray Echarri, Ana, Moure Rodríguez, María Dolores, Novo-Rodríguez, Cristina, Calatayud, María, Villar-Taibo, Rocío, Bernabéu, Ignacio, Alvarez-Escola, Cristina, Benítez Valderrama, Pamela, Tenorio-Jiménez, Carmen, Abellán Galiana, Pablo, Venegas, Eva, González-Molero, Inmaculada, Iglesias, Pedro, Blanco-Carrera, Concepción, Vidal-Ostos De Lara, Fernando, de Miguel Novoa, Paz, López Mezquita, Elena, Hanzu, Felicia Alexandra, Aldecoa, Iban, Aznar, Silvia, Lamas, Cristina, Aulinas, Anna, Asla, Queralt, Gracia Gimeno, Paola, Recio-Córdova, José María, Avilés-Pérez, María Dolores, Asensio-Wandosell, Diego, Sampedro-Núñez, Miguel, Cámara, Rosa, Paja Fano, Miguel, Ruz-Caracuel, Ignacio, Fajardo, Carmen, Marazuela, Mónica, Puig-Domingo, Manel |
| المصدر: | Endocr Relat Cancer ; ISSN:1479-6821 ; Volume:31 ; Issue:7 |
| بيانات النشر: | Sheridan PubFactory |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| مصطلحات موضوعية: | acromegaly, pasireotide, pegvisomant, pituitary neuroendocrine tumors, prolactin |
| الوصف: | The objective of the study was to evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH&PRL-Pit-NET) compared to their efficacy in patients with acromegaly caused by a GH-secreting pituitary neuroendocrine tumor (GH-Pit-NET). This is a multicenter retrospective study of patients with acromegaly on treatment with pasireotide and/or pegvisomant. Patients were classified in two groups: GH&PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were >200 ng/dL regardless of the PRL-IHC and GH-Pit-NETs when the previously mentioned criteria were not met. A total of 28 cases with GH&PRL-Pit-NETs and 122 with GH-Pit-NETs met the inclusion criteria. GH&PRL-Pit-NETs presented at a younger age, caused hypopituitarism, and were invasive more frequently than GH-Pit-NETs. There were 124 patients treated with pegvisomant and 49 with pasireotide at any time. The efficacy of pegvisomant for IGF-1 normalization was of 81.5% and of pasireotide of 71.4%. No differences in IGF-1 control with pasireotide and with pegvisomant were observed between GH&PRL-Pit-NETs and GH-Pit-NETs. All GH&PRL-Pit-NET cases treated with pasireotide (n = 6) and 82.6% (n = 19/23) of the cases treated with pegvisomant normalized PRL levels. No differences in the rate of IGF-1 control between pegvisomant and pasireotide were detected in patients with GH&PRL-Pit-NETs (84.9% vs 66.7%, P = 0.178). We conclude that despite the more aggressive behavior of GH&PRL-Pit-NETs than GH-Pit-NETs, no differences in the rate of IGF-1 control with pegvisomant and pasireotide were observed between both groups, and both drugs have shown to be effective treatments to control IGF-1 and PRL hypersecretion in these tumors. |
| نوع الوثيقة: | article in journal/newspaper report |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1530/ERC-24-0043Test; https://pubmed.ncbi.nlm.nih.gov/38713182Test |
| DOI: | 10.1530/ERC-24-0043 |
| الإتاحة: | https://doi.org/10.1530/ERC-24-0043Test https://pubmed.ncbi.nlm.nih.gov/38713182Test |
| رقم الانضمام: | edsbas.E9B41375 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1530/ERC-24-0043 |
|---|